Zscaler's $10 billion long-term ARR target looks ambitious, says Jefferies

Zscaler reaffirmed its first-quarter and fiscal 2027 guidance at its investor day, easing concerns tied to recent go-to-market leadership changes. Jefferies said the reaffirmation supports near-term growth confidence but called the company’s $10 billion annual recurring revenue target for fiscal 2031 ambitious.

Analysis

The reaffirmation reduces the near-term probability that sales-leadership changes disrupt execution, but it is evidence of stability—not incremental demand—and may have limited value if already reflected in expectations. The more consequential issue is whether the fiscal 2031 ARR ambition can be supported by durable customer expansion and efficient new-logo acquisition. Without the current ARR base, net-retention trends, and sales-efficiency data, the target cannot be judged quantitatively; treating it as a valuation anchor now risks paying for execution years before it is demonstrated.

Over the next few days, the guidance message may support sentiment, but the stock’s reaction should be measured against valuation and positioning rather than the headline alone. Over the next 1–3 months, watch reported growth, large-deal conversion, retention, and any evidence that go-to-market changes affect pipeline productivity. Over 6–18 months, sustained platform consolidation by customers could favor Zscaler, while aggressive competition from broader cybersecurity vendors could pressure deal economics and raise the cost of reaching the long-term target. The contrarian point: investors may over-credit a reaffirmation as proof the leadership transition is resolved, while underweighting the gap between near-term guidance and long-dated ARR ambition. No valuation or estimate data are provided to establish an attractive directional entry.

Key Decisions for Investors

• Do not chase a near-term move based solely on reaffirmed guidance; treat it as removal of a potential negative, not a new growth catalyst.
• Keep ZS on a watchlist for a staged long position only if subsequent results confirm healthy retention and sales productivity; verify the current ARR base and the implied growth path to fiscal 2031 first.
• For the next 1–3 months, monitor reported growth, retention, pipeline conversion, and management commentary on the sales reorganization. Weaken the thesis if guidance is cut or these operating indicators deteriorate.
• Avoid a peer pair trade until relative valuation and growth estimates are checked; the competitive mechanism is clear, but the supplied information does not establish mispricing.